ADGM MEXC RealStocks
Own real ADGM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 04:00:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Adagio Medical Holdings, Inc. (ADGM) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1.56, with a market capitalization of $1.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.45 to $50.70. This page covers its latest market performance, valuation, price trends and company information.
$1.47M | |
$1.63 | |
$1.64 | |
$1.53 | |
$1.65 | |
9.35K | |
92.95K | |
-- | |
$50.70 | |
$1.45 | |
-- | |
2026-06-30 |
Adagio Medical Holdings, Inc. (ADGM) last closed at $1.56 as of 2026-11-19 00:57:00, down 4.20% ($0.07) from the previous close of $1.65.
During the latest regular trading session, ADGM traded between $1.53 and $1.64, with a volume of 9.35K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Adagio Medical Holdings, Inc. (ADGM) moved from $1.92 to $1.56, representing a decline of 18.59% ($0.36).
The stock traded between $1.45 and $2.32 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 266.72 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.2%
ADGM is currently trading at $1.56, placing it 0.2% of the way from its 52-week low of $1.45 to its 52-week high of $50.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 41 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Adagio Medical Holdings, Inc.
Stock Split | |
|---|---|
| Split Date | Nov 9, 2026 |
| Split Ratio | 1-for-30 |
Eligible investors can buy real shares of Adagio Medical Holdings, Inc. (ADGM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ADGM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ADGM shares and USD.
ADGM Shares to USD
1.00 ADGM shares = 1.563 USD
Calculations are estimates based on the latest available price and are for reference only.